{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:42:11Z","timestamp":1789778531950,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.mce.2021.111180","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T21:58:25Z","timestamp":1611611905000},"page":"111180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Hormone replacement therapy after breast cancer: Yes, No or maybe?"],"prefix":"10.1016","volume":"525","author":[{"given":"Stacy K.","family":"Ugras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhshanda","family":"Layeequr Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mce.2021.111180_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000055319","article-title":"Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates","volume":"60","author":"Beckmann","year":"2001","journal-title":"Oncology"},{"issue":"14","key":"10.1016\/j.mce.2021.111180_bib2","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.295.14.1658","article-title":"Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer","volume":"295","author":"Berry","year":"2006","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.mce.2021.111180_bib3","doi-asserted-by":"crossref","first-page":"R535","DOI":"10.1186\/bcr1035","article-title":"Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence","volume":"7","author":"Col","year":"2005","journal-title":"Breast Cancer Res."},{"issue":"10","key":"10.1016\/j.mce.2021.111180_bib4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/GME.0000000000000219","article-title":"Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis","volume":"21","author":"Davis","year":"2014","journal-title":"Menopause"},{"issue":"6","key":"10.1016\/j.mce.2021.111180_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00000421-200012000-00001","article-title":"Breast cancer survival and hormone replacement therapy: a cohort analysis","volume":"23","author":"DiSaia","year":"2000","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.mce.2021.111180_bib6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/13697130400001380","article-title":"Breast cancer in premenopausal women: recurrence and survival rates and relationship to hormone replacement therapy","volume":"7","author":"Durna","year":"2004","journal-title":"Climacteric: J. Int. Menopause Soc."},{"issue":"5","key":"10.1016\/j.mce.2021.111180_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0305-7372(96)90006-7","article-title":"Hormone replacement therapy after breast cancer: a review","volume":"22","author":"Eden","year":"1996","journal-title":"Canc. Treat Rev."},{"issue":"1","key":"10.1016\/j.mce.2021.111180_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial","volume":"49","author":"Fahl\u00e9n","year":"2013","journal-title":"Eur. J. Canc."},{"issue":"11","key":"10.1016\/j.mce.2021.111180_bib9","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdz298","article-title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis","volume":"30","author":"Ferreira","year":"2019","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol.\/ESMO"},{"issue":"5","key":"10.1016\/j.mce.2021.111180_bib10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9407","key":"10.1016\/j.mce.2021.111180_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.mce.2021.111180_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.mce.2021.111180_bib13","first-page":"3813","article-title":"Characteristics of adverse events of endocrine therapies among older patients with breast cancer","volume":"27","author":"Honma","year":"2019","journal-title":"Support. Care Canc.: Off. J. Multinatl. Assoc. Support. Care Canc."},{"issue":"5","key":"10.1016\/j.mce.2021.111180_bib14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/jnci\/djr541","article-title":"Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review","volume":"104","author":"Howard-Anderson","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.mce.2021.111180_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","article-title":"Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial","volume":"10","author":"Kenemans","year":"2009","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.mce.2021.111180_bib16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.breast.2015.08.010","article-title":"SOFT trial can be very hard on young women","volume":"24","author":"Layeequr Rahman","year":"2015","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.mce.2021.111180_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/09513590.2012.705389","article-title":"Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy","volume":"29","author":"Mariani","year":"2013","journal-title":"Gynecol. Endocrinol.: Off. J. Int. Soc. Gynecol. Endocrinol."},{"issue":"12","key":"10.1016\/j.mce.2021.111180_bib18","first-page":"1056","article-title":"Cancer recurrence and mortality in women using hormone replacement therapy: meta-analysis","volume":"51","author":"Meurer","year":"2002","journal-title":"J. Fam. Pract."},{"issue":"5","key":"10.1016\/j.mce.2021.111180_bib19","first-page":"363","article-title":"Cancer treatment and survivorship statistics","volume":"69","author":"Miller","year":"2019","journal-title":"CA A Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.mce.2021.111180_bib20","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/GME.0000000000000546","article-title":"Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of the North American Menopause Society","volume":"22","year":"2015","journal-title":"Menopause"},{"issue":"10","key":"10.1016\/j.mce.2021.111180_bib21","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnci\/93.10.754","article-title":"Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality","volume":"93","author":"O'Meara","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.mce.2021.111180_bib22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.maturitas.2011.09.008","article-title":"Improving quality of life after breast cancer: dealing with symptoms","volume":"70","author":"Pinto","year":"2011","journal-title":"Maturitas"},{"issue":"7","key":"10.1016\/j.mce.2021.111180_bib23","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/annonc\/mdn037","article-title":"Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?","volume":"19","author":"Regan","year":"2008","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol.\/ESMO"},{"issue":"2","key":"10.1016\/j.mce.2021.111180_bib24","first-page":"87","article-title":"Global cancer statistics","volume":"65","author":"Torre","year":"2012","journal-title":"CA A Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.mce.2021.111180_bib25","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1200\/JCO.1999.17.5.1482","article-title":"Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively","volume":"17","author":"Vassilopoulou-Sellin","year":"1999","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.mce.2021.111180_bib26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Menopausal hormone therapy after breast cancer: the Stockholm randomized trial","volume":"97","author":"von Schoultz","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mce.2021.111180_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.breast.2018.05.002","article-title":"The oncologic impact of hormone replacement therapy in premenopausal breast cancer survivors: a systematic review","volume":"40","author":"Wang","year":"2018","journal-title":"Breast"}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720721000241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720721000241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:14:06Z","timestamp":1759587246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720721000241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":27,"alternative-id":["S0303720721000241"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2021.111180","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormone replacement therapy after breast cancer: Yes, No or maybe?","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2021.111180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111180"}}